+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Smart Inhalers Market Size, Share & Industry Trends Analysis Report By Product, By Disease Indication, By Distribution Channel, By Regional Outlook and Forecast, 2021-2027

  • PDF Icon

    Report

  • 205 Pages
  • March 2022
  • Region: Global
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5590254
The Global Smart Inhalers Market size is expected to reach $414.4 million by 2027, rising at a market growth of 24.9% CAGR during the forecast period.



Smart inhalers are inhalation devices that deliver a range of medications. Inhalers contain anticholinergic, glucocorticoids, insulin, and beta-agonists, which are used to treat and prevent respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). When sensors are placed as a clip to inhalers to monitor the proper dose per intake and the technique used for inhaling the drug, these inhalers are referred to as smart inhalers. The sensor's data is shared with the patient and healthcare practitioners in order to track inhaler usage. The monitored data is then exchanged with their mobile apps via an internet platform using Bluetooth technology, and electronic health records (EHR) or electronic medical records (EMR) are preserved as a result.

Some smart inhalers have sensors that can identify whether a person is in a polluted or pollen-filled environment, give useful reminders, and indicate if an individual's inhaler technique needs to be reviewed. Individuals do not need to maintain their own records because all inhalers are intended to automatically track how often they are used.

Indoor air pollution in households in underdeveloped and developing countries is becoming a more widespread problem with an increase in the population of these countries. Respiratory problems such as COPD and asthma are more common in people who live in substandard housing and neighborhoods. Inhalation of particles occurs when kerosene lights and portable stoves are used for heating and cooking. Furthermore, rising tobacco consumption among both men and women in high-income nations, as well as increased risk of indoor air pollution, are projected to raise the prevalence of respiratory disease in both men and women. Smoking, biomass fuel for heating and cooking, and poor ventilation are all sources of indoor pollution in low-income countries. As a result, an increase in indoor pollution is expected to lead to an increase in asthma and COPD cases, driving the market.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic has impacted various sectors of the business domain. The imposition of various restrictions like lockdown, ban on cross border travelling, social distancing norm, temporary ban on manufacturing units and ban on imports & exports, have disrupted the supply chain of various goods or products across the world. In addition, the burden on healthcare sector has increased due to the pandemic. The COVID-19 pandemic is expected to have a favorable impact on the market for smart inhalers. A large number of clinics and hospitals around the world have been reconfigured to boost hospital capacity for COVID-19 patients. Due to the substantial increase in COVID-19 cases, non-essential procedures may face a backlog.

Market driving Factors:


Increase in The Incidence of Chronic Respiratory Diseases

Asthma is the name of a chronic pulmonary disease by which both children and adults can be affected. Due to inflammation and tightening of the muscles around the tiny airways, the air channels in the lungs shrink. Asthma patients suffer from symptoms such as coughing, wheezing, shortness of breath, and chest tightness. These sensations are transitional, however, importantly, these symptoms worsen at night and during physical workouts. Asthma symptoms can be exacerbated by other common external and internal factors. Viral infections (colds), dust, smoke, fumes, changes in the weather, grass and tree pollen, animal fur and feathers, harsh soaps, and perfume are all potential triggers the intensity of the effects of the triggers that may vary from person to person.

Smart Inhalers are More Efficient Than Regular Inhalers

Smart inhalers are not only simply inhalers but any electronic devices capable of sharing data and tracking records. With the use of Bluetooth, digital inhalers may be connected to smartphones, allowing for dosing reminders and dose monitoring. Additionally, these devices have patient education tools that help to reduce dosing errors, resulting in lower hospitalization and treatment costs. The number of doctor visits of patients who utilized these types of inhalers fell dramatically. Increasing research and development about smart inhalers are likely to make them more effective and efficient, thus increasing their demand in the market.

Marketing Restraining Factor:


Smart Inhalers are Expensive

A smart inhaler is priced at around $99 on average. This varies based on the brand and the capabilities it offers. Naturally, the more sophisticated the capabilities, the more expensive they are. The same may be said for the cost of smart inhalers, which have sensors built into the device. Only specific medications and inhalers are authorized for use with some smart inhalers. As a result, double-checking the manufacturer's website or asking the pharmacist for further information about the inhaler, asthma treatments, and mobile device compatibility becomes essential. Purchasing medications can be costly, and purchasing equipment or devices to help manage the disease implies further expenses.

Product Outlook

Based on Product, the market is segmented into Metered Dose Inhalers (MDI's), and Dry Powdered Inhalers (DPIs). The dry powder inhaler (DPI) segment witnessed a significant revenue share in the smart inhalers market in 2020. A dry powder inhaler (DPI), which is a handheld device, can be used to administer certain drugs in the form of a dry powder. As users inhale through it, a DPI delivers medication to their lungs. There are no propellants or other substances in it; only the medication, which is propelling the growth of the segment.

Disease Indication Outlook

Based on Disease Indication, the market is segmented into Asthma, and Chronic Obstructive Pulmonary Disease (COPD). The asthma segment garnered the largest revenue share in the smart inhalers market in 2020. This is because of the sheer growing incidence of persons suffering from asthma. During the next few years, the segmental expansion will be fueled by a growing patient pool. In the United States, for example, 1 in 13 people have asthma, according to the Centers for Disease Control and Prevention (CDC). It is estimated that over 25 million Americans suffer from asthma. As a result, the rising prevalence of asthma, combined with rising public knowledge about the disease's risk, will drive the adoption of the smart inhalers market over the forecast period. The increase in demand for smart inhalers is likely to continue to do so during the forecast period.

Distribution Channel Outlook

Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies. The retail pharmacies segment observed a significant revenue share in the smart inhalers market in 2020. The increasing number of retail pharmacies around the world is responsible for the high increase. Furthermore, numerous smart inhaler manufacturers are stepping up their attempts to form partnerships with retail pharmacies in order to begin selling these devices over-the-counter, which will help the market grow even faster. Another key factor driving growth is the increasing number of FDA approvals for over-the-counter sales of digital inhalers. Adherium, for example, received FDA approval for over-the-counter sales of their digital inhaler sensor for AstraZeneca's asthma inhalation device in April 2018.

Regional Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. The North American segment acquired the largest revenue share of the smart inhalers market in 2020. This is due to improved healthcare infrastructure and services, a higher prevalence of asthma and COPD patients, the adoption of technologically sophisticated therapies, and increased healthcare expenditure in the region. People in North America tend to be more affluent than the population of the rest of the world and thus, the increasing adoption of smart inhalers in the region has not come to anyone’s surprise.

The major strategies followed by the market participants are Partnerships. Based on the Analysis presented in the Cardinal matrix; Novartis AG is the forerunners in the Smart Inhalers Market. Companies such as AstraZeneca, Inc., GlaxoSmithKline Plc, Teva Pharmaceutical Industries Ltd. are some of the key innovators in the Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Adherium Limited, Aptar Group Inc. (Cohero Health Inc.), AstraZeneca, Inc., Cognita Labs, LLC, GlaxoSmithKline Plc, Novartis AG, OPKO Health, Inc., Philip Morris International, Inc. (Vectura Group Plc), Resmed, Inc. (Propeller Health), and Teva Pharmaceutical Industries Ltd.
  • Feb 2022: Aptar Pharma introduced HeroTracker Sense, a novel digital respiratory health solution. The device is designed to enhance the health of patients across the world suffering from chronic respiratory diseases such as COPD, Cystic Fibrosis, asthma, and other respiratory conditions caused by COVID-19. Additionally, the device tracks their MDI usage and expedites enhanced adherence to their prescribed treatment.
  • Sep 2020: Teva Respiratory introduced ArmonAir Digihaler inhalation powder and AirDuo Digihaler inhalation powder. These two digital inhalers help in managing asthma inhalers among patients.
  • Jul 2020: Novartis received European Commission approval for glycopyrronium bromide, Enerzair Breezhaler, mometasone furoate, and indacaterol acetate for the treatment of asthma. Through this approval, the drugs provide precaution treatment in adult patients not appropriately controlled with a management combination of a long-acting beta2 agonist as well as a high-dose of an inhaled corticosteroid who experienced one or more asthma worsening in the previous year.
  • Apr 2020: Aptar teamed up with Sonmol, a leading Chinese digital respiratory therapeutics company. Under this collaboration, the companies focused on delivering connected digital platforms and drug delivery devices for chronic obstructive pulmonary and asthma disease. Moreover, this collaboration aimed to develop digital services and therapies platforms targeting respiratory and other diseases.
  • Jan 2020: Cognita Labs received the FDA approval for CapMedic, a smart inhaler cap. The device alerts patients to utilize inhalers in the right way. Additionally, Developers believe the feedback mechanism differentiates the device from other smart inhalers.
  • Jan 2020: Aptar Pharma joined hands with Lupin Limited, an Indian multinational pharmaceutical company. Together, the companies aimed to introduce India's first linked device for metered-dose inhalers called ADHERO. The smart device is developed to help patients with chronic respiratory diseases to track MDI utilization and facilitate enhanced attachment to their prescribed therapy.
  • Aug 2019: Adherium came into partnership with Summatix, a medical informatics company. Under this partnership, the companies empower doctors to improve the health of patients with chronic obstructive pulmonary and asthma diseases. Additionally, the Adherium post-reconstruction business model improves its platform abilities and sensor development by approaching and collaborating with dominant development houses to focus on insights on how data, and its application, is expected to influence the practice of medicine.
  • Jul 2019: ResMed took over Propeller Health, a digital therapeutics company providing connected health solutions. Through this partnership, Propeller's digital solutions strengthen ResMed's large portfolio of products that can treat millions of people at multiple stages of their COPD and other chronic diseases, all aimed at enhancing people's condition of life, while minimizing the effects of these hospitalizations, diseases, and the overall price of healthcare.
  • Aug 2018: Adherium introduced the Hailie solution in the U.S. The Food and Drug Administration approved that Hailie assists COPD and asthma patients to approach better precaution through a consistent digital experience that includes a smartphone app, available on both Android and iOS, along with a sensor that adheres to the patient's prescription inhaler medication.
  • Sep 2017: Adherium received the FDA approval for clearance for its new SmartTouch for Symbicort, inhaler monitoring technology for AstraZeneca's Symbicort aerosol inhaler. Through this approval, Symbicort equipped into patient's inhaler to monitor and boost medication adherence as part of a self-administration plan.
  • Sep 2017: GlaxoSmithKline expanded its partnership with Propeller Health, a mobile platform that offers sensors, mobile apps, analytics, and services to support respiratory health management. Together, the companies aimed to design digital solutions for asthma and chronic obstructive pulmonary disorder.
  • Jan 2017: AstraZeneca received the FDA approval for Symbicort Inhalation Aerosol 80/4.5 micrograms. The medicine is introduced for the treatment of asthma in pediatric patients from age six up to 12 years. Additionally, Symbicort's FDA approval was based on the CHASE clinical trial program, including the CHASE 3 Phase III trial.

Scope of the Study


Market Segments Covered in the Report:


By Product

  • Metered Dose Inhalers (MDI's)
  • Dry Powdered Inhalers (DPIs)

By Disease Indication

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)

By Distribution Channel

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players


List of Companies Profiled in the Report:

  • Adherium Limited
  • Aptar Group Inc. (Cohero Health Inc.)
  • AstraZeneca, Inc.
  • Cognita Labs, LLC
  • GlaxoSmithKline Plc
  • Novartis AG
  • OPKO Health, Inc.
  • Philip Morris International, Inc. (Vectura Group Plc)
  • Resmed, Inc. (Propeller Health)
  • Teva Pharmaceutical Industries Ltd.

Unique Offerings from the publisher

  • Exhaustive coverage
  • The highest number of market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Smart Inhalers Market, by Product
1.4.2 Global Smart Inhalers Market, by Disease Indication
1.4.3 Global Smart Inhalers Market, by Distribution Channel
1.4.4 Global Smart Inhalers Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Publisher Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
Chapter 4. Global Smart Inhalers Market by Product
4.1 Global Metered Dose Inhalers (MDI's) Market by Region
4.2 Global Dry Powdered Inhalers (DPIs) Market by Region
Chapter 5. Global Smart Inhalers Market by Disease Indication
5.1 Global Asthma Market by Region
5.2 Global Chronic Obstructive Pulmonary Disease (COPD) Market by Region
Chapter 6. Global Smart Inhalers Market by Distribution Channel
6.1 Global Hospitals Pharmacies Market by Region
6.2 Global Retail Pharmacies Market by Region
6.3 Global Online Pharmacies Market by Region
Chapter 7. Global Smart Inhalers Market by Region
7.1 North America Smart Inhalers Market
7.1.1 North America Smart Inhalers Market by Product
7.1.1.1 North America Metered Dose Inhalers (MDI's) Market by Country
7.1.1.2 North America Dry Powdered Inhalers (DPIs) Market by Country
7.1.2 North America Smart Inhalers Market by Disease Indication
7.1.2.1 North America Asthma Market by Country
7.1.2.2 North America Chronic Obstructive Pulmonary Disease (COPD) Market by Country
7.1.3 North America Smart Inhalers Market by Distribution Channel
7.1.3.1 North America Hospitals Pharmacies Market by Country
7.1.3.2 North America Retail Pharmacies Market by Country
7.1.3.3 North America Online Pharmacies Market by Country
7.1.4 North America Smart Inhalers Market by Country
7.1.4.1 US Smart Inhalers Market
7.1.4.1.1 US Smart Inhalers Market by Product
7.1.4.1.2 US Smart Inhalers Market by Disease Indication
7.1.4.1.3 US Smart Inhalers Market by Distribution Channel
7.1.4.2 Canada Smart Inhalers Market
7.1.4.2.1 Canada Smart Inhalers Market by Product
7.1.4.2.2 Canada Smart Inhalers Market by Disease Indication
7.1.4.2.3 Canada Smart Inhalers Market by Distribution Channel
7.1.4.3 Mexico Smart Inhalers Market
7.1.4.3.1 Mexico Smart Inhalers Market by Product
7.1.4.3.2 Mexico Smart Inhalers Market by Disease Indication
7.1.4.3.3 Mexico Smart Inhalers Market by Distribution Channel
7.1.4.4 Rest of North America Smart Inhalers Market
7.1.4.4.1 Rest of North America Smart Inhalers Market by Product
7.1.4.4.2 Rest of North America Smart Inhalers Market by Disease Indication
7.1.4.4.3 Rest of North America Smart Inhalers Market by Distribution Channel
7.2 Europe Smart Inhalers Market
7.2.1 Europe Smart Inhalers Market by Product
7.2.1.1 Europe Metered Dose Inhalers (MDI's) Market by Country
7.2.1.2 Europe Dry Powdered Inhalers (DPIs) Market by Country
7.2.2 Europe Smart Inhalers Market by Disease Indication
7.2.2.1 Europe Asthma Market by Country
7.2.2.2 Europe Chronic Obstructive Pulmonary Disease (COPD) Market by Country
7.2.3 Europe Smart Inhalers Market by Distribution Channel
7.2.3.1 Europe Hospitals Pharmacies Market by Country
7.2.3.2 Europe Retail Pharmacies Market by Country
7.2.3.3 Europe Online Pharmacies Market by Country
7.2.4 Europe Smart Inhalers Market by Country
7.2.4.1 Germany Smart Inhalers Market
7.2.4.1.1 Germany Smart Inhalers Market by Product
7.2.4.1.2 Germany Smart Inhalers Market by Disease Indication
7.2.4.1.3 Germany Smart Inhalers Market by Distribution Channel
7.2.4.2 UK Smart Inhalers Market
7.2.4.2.1 UK Smart Inhalers Market by Product
7.2.4.2.2 UK Smart Inhalers Market by Disease Indication
7.2.4.2.3 UK Smart Inhalers Market by Distribution Channel
7.2.4.3 France Smart Inhalers Market
7.2.4.3.1 France Smart Inhalers Market by Product
7.2.4.3.2 France Smart Inhalers Market by Disease Indication
7.2.4.3.3 France Smart Inhalers Market by Distribution Channel
7.2.4.4 Russia Smart Inhalers Market
7.2.4.4.1 Russia Smart Inhalers Market by Product
7.2.4.4.2 Russia Smart Inhalers Market by Disease Indication
7.2.4.4.3 Russia Smart Inhalers Market by Distribution Channel
7.2.4.5 Spain Smart Inhalers Market
7.2.4.5.1 Spain Smart Inhalers Market by Product
7.2.4.5.2 Spain Smart Inhalers Market by Disease Indication
7.2.4.5.3 Spain Smart Inhalers Market by Distribution Channel
7.2.4.6 Italy Smart Inhalers Market
7.2.4.6.1 Italy Smart Inhalers Market by Product
7.2.4.6.2 Italy Smart Inhalers Market by Disease Indication
7.2.4.6.3 Italy Smart Inhalers Market by Distribution Channel
7.2.4.7 Rest of Europe Smart Inhalers Market
7.2.4.7.1 Rest of Europe Smart Inhalers Market by Product
7.2.4.7.2 Rest of Europe Smart Inhalers Market by Disease Indication
7.2.4.7.3 Rest of Europe Smart Inhalers Market by Distribution Channel
7.3 Asia Pacific Smart Inhalers Market
7.3.1 Asia Pacific Smart Inhalers Market by Product
7.3.1.1 Asia Pacific Metered Dose Inhalers (MDI's) Market by Country
7.3.1.2 Asia Pacific Dry Powdered Inhalers (DPIs) Market by Country
7.3.2 Asia Pacific Smart Inhalers Market by Disease Indication
7.3.2.1 Asia Pacific Asthma Market by Country
7.3.2.2 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Market by Country
7.3.3 Asia Pacific Smart Inhalers Market by Distribution Channel
7.3.3.1 Asia Pacific Hospitals Pharmacies Market by Country
7.3.3.2 Asia Pacific Retail Pharmacies Market by Country
7.3.3.3 Asia Pacific Online Pharmacies Market by Country
7.3.4 Asia Pacific Smart Inhalers Market by Country
7.3.4.1 China Smart Inhalers Market
7.3.4.1.1 China Smart Inhalers Market by Product
7.3.4.1.2 China Smart Inhalers Market by Disease Indication
7.3.4.1.3 China Smart Inhalers Market by Distribution Channel
7.3.4.2 Japan Smart Inhalers Market
7.3.4.2.1 Japan Smart Inhalers Market by Product
7.3.4.2.2 Japan Smart Inhalers Market by Disease Indication
7.3.4.2.3 Japan Smart Inhalers Market by Distribution Channel
7.3.4.3 India Smart Inhalers Market
7.3.4.3.1 India Smart Inhalers Market by Product
7.3.4.3.2 India Smart Inhalers Market by Disease Indication
7.3.4.3.3 India Smart Inhalers Market by Distribution Channel
7.3.4.4 South Korea Smart Inhalers Market
7.3.4.4.1 South Korea Smart Inhalers Market by Product
7.3.4.4.2 South Korea Smart Inhalers Market by Disease Indication
7.3.4.4.3 South Korea Smart Inhalers Market by Distribution Channel
7.3.4.5 Singapore Smart Inhalers Market
7.3.4.5.1 Singapore Smart Inhalers Market by Product
7.3.4.5.2 Singapore Smart Inhalers Market by Disease Indication
7.3.4.5.3 Singapore Smart Inhalers Market by Distribution Channel
7.3.4.6 Malaysia Smart Inhalers Market
7.3.4.6.1 Malaysia Smart Inhalers Market by Product
7.3.4.6.2 Malaysia Smart Inhalers Market by Disease Indication
7.3.4.6.3 Malaysia Smart Inhalers Market by Distribution Channel
7.3.4.7 Rest of Asia Pacific Smart Inhalers Market
7.3.4.7.1 Rest of Asia Pacific Smart Inhalers Market by Product
7.3.4.7.2 Rest of Asia Pacific Smart Inhalers Market by Disease Indication
7.3.4.7.3 Rest of Asia Pacific Smart Inhalers Market by Distribution Channel
7.4 LAMEA Smart Inhalers Market
7.4.1 LAMEA Smart Inhalers Market by Product
7.4.1.1 LAMEA Metered Dose Inhalers (MDI's) Market by Country
7.4.1.2 LAMEA Dry Powdered Inhalers (DPIs) Market by Country
7.4.2 LAMEA Smart Inhalers Market by Disease Indication
7.4.2.1 LAMEA Asthma Market by Country
7.4.2.2 LAMEA Chronic Obstructive Pulmonary Disease (COPD) Market by Country
7.4.3 LAMEA Smart Inhalers Market by Distribution Channel
7.4.3.1 LAMEA Hospitals Pharmacies Market by Country
7.4.3.2 LAMEA Retail Pharmacies Market by Country
7.4.3.3 LAMEA Online Pharmacies Market by Country
7.4.4 LAMEA Smart Inhalers Market by Country
7.4.4.1 Brazil Smart Inhalers Market
7.4.4.1.1 Brazil Smart Inhalers Market by Product
7.4.4.1.2 Brazil Smart Inhalers Market by Disease Indication
7.4.4.1.3 Brazil Smart Inhalers Market by Distribution Channel
7.4.4.2 Argentina Smart Inhalers Market
7.4.4.2.1 Argentina Smart Inhalers Market by Product
7.4.4.2.2 Argentina Smart Inhalers Market by Disease Indication
7.4.4.2.3 Argentina Smart Inhalers Market by Distribution Channel
7.4.4.3 UAE Smart Inhalers Market
7.4.4.3.1 UAE Smart Inhalers Market by Product
7.4.4.3.2 UAE Smart Inhalers Market by Disease Indication
7.4.4.3.3 UAE Smart Inhalers Market by Distribution Channel
7.4.4.4 Saudi Arabia Smart Inhalers Market
7.4.4.4.1 Saudi Arabia Smart Inhalers Market by Product
7.4.4.4.2 Saudi Arabia Smart Inhalers Market by Disease Indication
7.4.4.4.3 Saudi Arabia Smart Inhalers Market by Distribution Channel
7.4.4.5 South Africa Smart Inhalers Market
7.4.4.5.1 South Africa Smart Inhalers Market by Product
7.4.4.5.2 South Africa Smart Inhalers Market by Disease Indication
7.4.4.5.3 South Africa Smart Inhalers Market by Distribution Channel
7.4.4.6 Nigeria Smart Inhalers Market
7.4.4.6.1 Nigeria Smart Inhalers Market by Product
7.4.4.6.2 Nigeria Smart Inhalers Market by Disease Indication
7.4.4.6.3 Nigeria Smart Inhalers Market by Distribution Channel
7.4.4.7 Rest of LAMEA Smart Inhalers Market
7.4.4.7.1 Rest of LAMEA Smart Inhalers Market by Product
7.4.4.7.2 Rest of LAMEA Smart Inhalers Market by Disease Indication
7.4.4.7.3 Rest of LAMEA Smart Inhalers Market by Distribution Channel
Chapter 8. Company Profiles
8.1 Adherium Limited
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Product Launches and Product Expansions:
8.1.5.2 Approvals and Trials:
8.2 GlaxoSmithKline PLC (GSK)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.3 Teva Pharmaceutical Industries Ltd.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Product Launches and Product Expansions:
8.4 AstraZeneca PLC
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Approvals and Trials:
8.5 OPKO Health, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expenses
8.6 Aptar Group, Inc. (Cohero Health Inc.)
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Product Launches and Product Expansions:
8.7 Novartis AG
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 Recent strategies and developments:
8.7.5.1 Approvals and Trials:
8.8 ResMed, Inc. (Propeller Health)
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments:
8.8.5.1 Acquisition and Mergers:
8.9 Cognita Labs, LLC
8.9.1 Company Overview
8.9.2 Recent strategies and developments:
8.9.2.1 Approvals and Trials:
8.10. Vectura Group plc (Philip Morris International, Inc.)
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expenses

Companies Mentioned

  • Adherium Limited
  • Aptar Group Inc. (Cohero Health Inc.)
  • AstraZeneca, Inc.
  • Cognita Labs, LLC
  • GlaxoSmithKline Plc
  • Novartis AG
  • OPKO Health, Inc.
  • Philip Morris International, Inc. (Vectura Group Plc)
  • Resmed, Inc. (Propeller Health)
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...